2.155USD-4.65%Mkt Cap: 9.52M USDP/E: —Last update: 2026-05-26
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap9.52M USD
Enterprise Value82.43M USD
Revenue (TTM)20.94K USD
Gross Profit20.94K USD
Net Income (TTM)-178.01M USD
Revenue/Share0.0010 USD
Last Price2.155 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-8.46
EV/Revenue3936.31
P/S62.81
P/B-0.52
EPS (TTM)-61.52
EPS (Forward)—
52W Range
1.2083% of range36.00
52W High36.00 USD
52W Low1.208 USD
Profitability
Gross Margin100.00%
Oper. Margin-6815.30%
EBITDA Margin0.00%
Profit Margin0.00%
ROE833.76%
ROA-2162.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.87M USD
CapEx (TTM)—
FCF Margin-16265.53%
FCF Yield-35.78%
Net Debt-1.74M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity-0.48
Current Ratio0.19
Quick Ratio0.16
Book Value/Sh-0.5600 USD
Cash/Share0.0870 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateMay 22, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.53M
Float26.79M
Insiders31.35%
Institutions2.73%
Short Interest
Short Ratio0.2d
Short % Float5.23%
Short % Out.4.56%
Shares Short206.77K
Short (prev mo.)188.66K
Technical
SMA 502.739 (-21.3%)
SMA 2007.699 (-72.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)882.77K
Avg Vol (10d)132.29K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—